By SmashMeals Editorial — 2026-10-01 — Health & Nutrition
The short answer
Survodutide remains investigational. In the Phase 3 SYNCHRONIZE-1 trial, adults with overweight or obesity without diabetes receiving once-weekly survodutide had substantially greater mean weight loss than placebo over 76 weeks. The drug activates GLP-1 and glucagon receptors; gastrointestinal adverse events were the most common side effects.
Key facts
- SYNCHRONIZE-1 was a Phase 3 randomized placebo-controlled trial.
- Survodutide is a dual GLP-1/glucagon receptor agonist.
- The trial enrolled adults with overweight or obesity without diabetes.
- Weight loss was substantially greater with survodutide than placebo across tested maintenance doses.
- Survodutide remains investigational and is not an FDA-approved obesity medication.
KINGSPORT, Tenn., Oct. 1, 2026 — Retatrutide is not the only next-generation obesity drug moving through Phase 3. Survodutide, an investigational once-weekly dual agonist targeting GLP-1 and glucagon receptors, has peer-reviewed Phase 3 obesity data from the SYNCHRONIZE-1 trial.
Survodutide is investigational. This is research reporting, not medication advice or a recommendation to obtain an unapproved drug.
What the Phase 3 trial tested
SYNCHRONIZE-1 randomized adults with overweight or obesity without diabetes to several maintenance doses of survodutide or placebo for 76 weeks, alongside lifestyle intervention. The trial reported substantially greater mean weight reduction with survodutide than placebo.
The nutrition question comes after the efficacy headline
When obesity therapies substantially reduce appetite and body weight, the practical food questions include whether a person is still getting enough protein, fluids, micronutrients and overall energy. Those needs are individualized; they should not be replaced by a viral “survodutide diet.”
Where SmashMeals fits — and where it does not
SmashMeals can simplify food preparation and make nutrition information visible. It does not provide survodutide, recommend investigational therapy or claim that particular meals improve drug efficacy. For current approved therapies, start with our GLP-1 nutrition hub.
Commentary, not medical advice
The SmashMeals perspective
There is no established 'survodutide diet.' The responsible food conversation is about the same practical issues clinicians already monitor with appetite-altering obesity therapy: adequate nutrition, protein, hydration, tolerability and preserving strength. SmashMeals can provide transparent prepared-food options; it cannot prescribe a protocol for an investigational drug.
Sources & experts referenced
Sources are included for verification. No expert listed here endorses SmashMeals.
- Survodutide for Treatment of Obesity — New England Journal of Medicine
Why it matters: Primary peer-reviewed Phase 3 SYNCHRONIZE-1 publication. - Survodutide Phase III SYNCHRONIZE-1 trial results — Boehringer Ingelheim
Why it matters: Developer context on the investigational program and trial.